Next quarter’s earnings estimate for 2137 is -HK$0.07 with a range of -HK$0.07 to -HK$0.07. The previous quarter’s EPS was -HK$0.22. 2137 beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year 2137 has Outperformed its overall industry.
Next quarter’s earnings estimate for 2137 is -HK$0.07 with a range of -HK$0.07 to -HK$0.07. The previous quarter’s EPS was -HK$0.22. 2137 beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year 2137 has Outperformed its overall industry.
2137 Sales Forecast
Next quarter’s sales forecast for 2137 is HK$0.00 with a range of HK$0.00 to HK$0.00. The previous quarter’s sales results were HK$0.00. 2137 beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year 2137 has Performed in-line its overall industry.
Next quarter’s sales forecast for 2137 is HK$0.00 with a range of HK$0.00 to HK$0.00. The previous quarter’s sales results were HK$0.00. 2137 beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year 2137 has Performed in-line its overall industry.
Leerink Partners Reaffirms Their Hold Rating on Brii Biosciences Limited (7SS)Leerink Partners analyst Roanna Ruiz raised the price target on Brii Biosciences Ltd (2137:HK) to HK$2.00 (from HK$1.00) while maintaining a Market Perform rating.
Leerink Partners Reaffirms Their Hold Rating on Brii Biosciences Limited (7SS)Leerink Partners analyst Roanna Ruiz raised the price target on Brii Biosciences Ltd (2137:HK) to HK$2.00 (from HK$1.00) while maintaining a Market Perform rating.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.
2137 Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
0
0
0
0
0
Buy
1
0
0
0
0
Hold
2
5
9
13
12
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
3
5
9
13
12
In the current month, 2137 has received 0Buy Ratings, 12Hold Ratings, and 0Sell Ratings. 2137 average Analyst price target in the past 3 months is ―.
Each month's total comprises the sum of three months' worth of ratings.
2137 Stock Forecast FAQ
What is HK:2137’s average 12-month price target, according to analysts?
Currently, no data Available
What is HK:2137’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for HK:2137, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Brii Biosciences Limited a Buy, Sell or Hold?
Brii Biosciences Limited has a consensus rating of Hold, which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.
What is Brii Biosciences Limited’s share price target?
Currently, no data Available
What do analysts say about Brii Biosciences Limited?
Brii Biosciences Limited’s analyst rating consensus is a Hold. This is based on the ratings of 0 Wall Streets Analysts.
How can I buy shares of Brii Biosciences Limited?
To buy shares of HK:2137, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.